Consilient Health is to launch Cytisine 1.5mg tablets in the UK from January 2024.
The product is a proven and well-tolerated medication derived from a plant alkaloid with a structure akin to nicotine. It is a promising solution for individuals looking to break free from nicotine dependence and quit smoking.
Cytisine has received approval from the MHRA and is licensed for "smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking" with the goal of treatment being “the permanent cessation of the nicotine containing products use”.
Cytisine is taken orally following a reducing dosing schedule over just 25 days.
Its mechanism of action is key to its effectiveness. It acts as a nicotine receptor partial agonist, binding to the same receptors responsible for nicotine dependence. This stimulates the release of dopamine, similar to nicotine, while also preventing nicotine from binding to the receptor. This dual action helps alleviate nicotine withdrawal symptoms and reduce the rewarding effects of tobacco.
One pack containing 100 tablets, sufficient for the 25-day recommended treatment course, is priced at £115.
Cytisine is available from all main wholesalers from January 22.
For general product queries email infouk@consilienthealth.com